Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.
作者信息
Boyarsky Brian J, Ruddy Jake A, Connolly Caoilfhionn M, Ou Michael T, Werbel William A, Garonzik-Wang Jacqueline M, Segev Dorry L, Paik Julie J
机构信息
Surgery, Johns Hopkins University, Baltimore, Maryland, USA.
Rheumatology, Johns Hopkins Unveristy, Baltimore, Maryland, USA.
出版信息
Ann Rheum Dis. 2021 Aug;80(8):1098-1099. doi: 10.1136/annrheumdis-2021-220289. Epub 2021 Mar 23.
Abstract
摘要
相似文献
1
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.风湿性和肌肉骨骼疾病患者对单剂SARS-CoV-2 mRNA疫苗的抗体反应。
Ann Rheum Dis. 2021 Aug;80(8):1098-1099. doi: 10.1136/annrheumdis-2021-220289. Epub 2021 Mar 23.
2
Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study.五种不同的新型冠状病毒2疫苗在病情缓解或疾病活动度低的自身免疫性风湿和肌肉骨骼疾病患者及健康对照中的体液和细胞免疫原性及安全性：一项单中心研究
Front Immunol. 2022 Mar 31;13:846248. doi: 10.3389/fimmu.2022.846248. eCollection 2022.
3
Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine.风湿性肌肉骨骼疾病患者接受 SARS-CoV-2 mRNA 疫苗后疾病发作频率较低。
Arthritis Res Ther. 2022 Jan 11;24(1):21. doi: 10.1186/s13075-021-02674-w.
4
Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial.使用疾病修正抗风湿药物的系统性自身免疫性风湿病患者接种第四剂 COVID-19 mRNA 疫苗的效果：模拟目标试验。
Lancet Rheumatol. 2024 Jan;6(1):e21-e30. doi: 10.1016/S2665-9913(23)00272-2. Epub 2023 Nov 15.
5
Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases.风湿性和肌肉骨骼疾病患者对杨森/强生公司的新型冠状病毒疫苗的抗体反应。
Ann Rheum Dis. 2021 Oct;80(10):1365-1366. doi: 10.1136/annrheumdis-2021-221145. Epub 2021 Aug 24.
6
Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic Diseases.利妥昔单抗治疗后时间对于风湿性疾病患者对 COVID-19 mRNA 疫苗产生体液免疫反应至关重要。
J Rheumatol. 2022 Jun;49(6):644-649. doi: 10.3899/jrheum.211152. Epub 2022 Mar 1.
7
Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.健康受试者对 mRNA COVID-19 疫苗的抗体反应差异。
Microbiol Spectr. 2021 Sep 3;9(1):e0034121. doi: 10.1128/Spectrum.00341-21. Epub 2021 Aug 4.
8
Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases.免疫介导的炎症性风湿病患者对 SARS-CoV-2 mRNA 疫苗的免疫反应。
RMD Open. 2022 Jan;8(1). doi: 10.1136/rmdopen-2021-001898.
9
Humoral Immune Response to SARS-CoV-2 Vaccines in Patients with Autoimmune Rheumatic Diseases.自身免疫性风湿病患者对SARS-CoV-2疫苗的体液免疫反应
Arch Med Res. 2025 Apr;56(3):103141. doi: 10.1016/j.arcmed.2024.103141. Epub 2025 Jan 6.
10
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.在一项单中心队列研究中，慢性炎症性疾病和免疫抑制治疗患者的抗 SARS-CoV-2 mRNA 疫苗的免疫原性和安全性。
Ann Rheum Dis. 2021 Oct;80(10):1306-1311. doi: 10.1136/annrheumdis-2021-220272. Epub 2021 Mar 24.
引用本文的文献
1
4th booster-dose SARS-CoV-2 heterologous and homologous vaccination in rheumatological patients.风湿免疫病患者接种第 4 剂 SARS-CoV-2 异源和同源加强疫苗。
Front Immunol. 2024 Jul 26;15:1427501. doi: 10.3389/fimmu.2024.1427501. eCollection 2024.
2
Patients with juvenile idiopathic arthritis have decreased clonal diversity in the CD8 T cell repertoire response to influenza vaccination.青少年特发性关节炎患者对流感疫苗的 CD8 T 细胞反应中克隆多样性降低。
Front Immunol. 2024 May 30;15:1306490. doi: 10.3389/fimmu.2024.1306490. eCollection 2024.
3
Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases.与自身免疫性疾病患者对 SARS-CoV-2 疫苗免疫反应相关的因素。
JCI Insight. 2024 Jun 4;9(13):e180750. doi: 10.1172/jci.insight.180750.
4
COVID-19 Vaccine Effectiveness among Patients with Psoriatic Disease: A Population-Based Study.银屑病患者中COVID-19疫苗的有效性：一项基于人群的研究。
Vaccines (Basel). 2024 Apr 24;12(5):453. doi: 10.3390/vaccines12050453.
5
Long-term outcomes of COVID-19 vaccination in patients with rare and complex connective tissue diseases: The ERN-ReCONNET VACCINATE study.罕见和复杂结缔组织病患者新冠病毒疫苗接种的长期结果：ERN-ReCONNET疫苗接种研究
J Transl Autoimmun. 2023 Nov 28;7:100221. doi: 10.1016/j.jtauto.2023.100221. eCollection 2023 Dec.
6
COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases.免疫介导的炎症性疾病中的 COVID-19 疫苗接种与免疫抑制治疗
Vaccines (Basel). 2023 Dec 4;11(12):1813. doi: 10.3390/vaccines11121813.
7
Efficacy of coronavirus disease 2019 vaccines in patients with rheumatic diseases.2019冠状病毒病疫苗在风湿病患者中的疗效。
Arch Rheumatol. 2023 Feb 2;38(3):419-428. doi: 10.46497/ArchRheumatol.2023.9676. eCollection 2023 Sep.
8
Side effects of COVID-19 vaccines in the middle eastern population.中东人群中 COVID-19 疫苗的副作用。
Front Immunol. 2023 Nov 3;14:1270187. doi: 10.3389/fimmu.2023.1270187. eCollection 2023.
9
Rituximab, but not other biologics, impairs humoral immunity in patients with rheumatoid arthritis-a study using CoVariant protein arrays.利妥昔单抗而非其他生物制剂会损害类风湿性关节炎患者的体液免疫——一项使用CoVariant蛋白质阵列的研究
Rheumatol Adv Pract. 2023 Oct 12;7(3):rkad085. doi: 10.1093/rap/rkad085. eCollection 2023.
10
The effects of methotrexate on the immune responses to the COVID-19 vaccines in the patients with immune-mediated inflammatory disease: A systematic review of clinical evidence.甲氨蝶呤对免疫介导的炎症性疾病患者 COVID-19 疫苗免疫反应的影响：临床证据的系统评价。
Transpl Immunol. 2023 Aug;79:101858. doi: 10.1016/j.trim.2023.101858. Epub 2023 May 24.
Zotero 插件